09.09.2021 Vivoryon Therapeutics N.V.  NL00150002Q7

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference


 

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Conference
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

09.09.2021 / 16:41
The issuer is solely responsible for the content of this announcement.


Vivoryon Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference


Halle (Saale) / Munich, Germany, September 9, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, announced today that Ulrich Dauer, PhD, the Company's Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday September 13, 2021, at 7:00 am ET.
 

A replay of the webcast can be accessed from the Presentations & Webcasts page under News and Events on Vivoryon's website, www.vivoryon.com. The replay will be archived on Vivoryon's website for 30 days after the call.
 

###
 

For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.

Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Email: [email protected]
 

Media Contact
Trophic Communications

Valeria Fisher / Sophia Hergenhan
Tel: +49 175 8041816
Email: [email protected]
 

About Vivoryon Therapeutics N.V.
Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer's disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com
 



09.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Vivoryon Therapeutics N.V.
Weinbergweg 22
06120 Halle/Saale
Germany
Phone: +49 (0)345 555 9900
Fax: +49 (0)345 555 9901
E-mail: [email protected]
Internet: www.vivoryon.com
ISIN: NL00150002Q7
WKN: A2QJV6
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam
EQS News ID: 1232472

 
End of News DGAP News Service

1232472  09.09.2021 

fncls.ssp?fn=show_t_gif&application_id=1232472&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBITDA1,2 -13,39 -13,67 -9,86 -7,68 -7,63 -15,87 0,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBIT1,4 -13,39 -13,77 -9,96 -7,70 -7,72 -16,01 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Jahresüberschuss1 -13,51 -13,89 -8,01 -7,74 -7,82 -16,51 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Cashflow1,7 -12,15 -13,26 -12,12 -6,99 -11,61 -14,01 0,00
Ergebnis je Aktie8 -1,97 -1,82 -0,98 -0,94 -0,62 -0,83 -0,51
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Vivoryon Therapeutics
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2QJV6 17,820 355,96
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -16,39
KBV KCV KUV EV/EBITDA
16,85 - 0,00 -20,90
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,00 0,00 0,00 28.06.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
25.06.2021 21.09.2021 04.11.2021 30.04.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-4,72% 3,83% 95,18% 163,22%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Vivoryon Therapeutics N.V.  ISIN: NL00150002Q7 können Sie bei DGAP abrufen

Biotechnologie , A2QJV6 , 05Y , XETR:PB9